What are the recommended pharmacologic and non‑pharmacologic treatments for adult insomnia, including dosing, duration, and contraindications?

Medications for Sleep in Adults with Insomnia

Cognitive Behavioral Therapy for Insomnia (CBT-I) must be initiated immediately as first-line treatment for all adults with chronic insomnia, either before or alongside any medication, because it provides superior long-term efficacy with sustained benefits after drug discontinuation. 1, 2, 3

First-Line Non-Pharmacologic Treatment (Mandatory Foundation)

CBT-I is the standard of care and demonstrates better outcomes than medication alone, with improvements persisting for up to 2 years after therapy ends, whereas medication effects cease when stopped. 2, 3

Core CBT-I Components (All Required)

• Stimulus control therapy: Use the bed only for sleep; leave the bed if unable to fall asleep within 20 minutes and return only when drowsy. 2, 4
• Sleep restriction therapy: Limit time in bed to actual sleep time plus 30 minutes (minimum 5 hours), adjusting weekly based on sleep efficiency (total sleep time ÷ time in bed × 100%). 2, 3
• Cognitive restructuring: Challenge maladaptive beliefs such as "I cannot sleep without medication" or "My life will be ruined if I can't sleep." 2, 3
• Relaxation techniques: Progressive muscle relaxation, guided imagery, or controlled breathing to lower physiological arousal. 2, 4, 5
• Sleep hygiene education: Maintain consistent sleep-wake times, avoid caffeine ≥6 hours before bedtime, eliminate screens ≥1 hour before sleep, keep bedroom dark/quiet/cool. 2, 3, 4

Sleep hygiene education alone is insufficient as monotherapy; it must be combined with stimulus control and sleep restriction to achieve sustained improvement. 2, 3

CBT-I can be delivered via individual therapy, group sessions, telephone-based programs, web-based modules, or self-help books—all formats show comparable effectiveness. 2, 3

---

First-Line Pharmacologic Options (Only After CBT-I Initiation)

For Sleep-Onset Insomnia

Zolpidem 10 mg (5 mg if age ≥65 years) shortens sleep-onset latency by ~25 minutes and increases total sleep time by ~29 minutes; take within 30 minutes of bedtime with ≥7 hours remaining before awakening. 1, 2, 3, 4

Zaleplon 10 mg (5 mg if age ≥65 years) has an ultrashort half-life (~1 hour), provides rapid sleep initiation with minimal next-day sedation, and can be taken middle-of-night when ≥4 hours remain before awakening. 1, 2, 3, 4

Ramelteon 8 mg is a melatonin-receptor agonist with no abuse potential, no DEA scheduling, and no withdrawal symptoms, making it the preferred choice for patients with substance-use history. 1, 2, 3, 4

For Sleep-Maintenance Insomnia

Low-dose doxepin 3–6 mg is the preferred first-line option for sleep-maintenance insomnia, reducing wake after sleep onset by 22–23 minutes with minimal anticholinergic effects at hypnotic doses and no abuse potential. 1, 2, 3, 4

• Start doxepin 3 mg at bedtime; if insufficient after 1–2 weeks, increase to 6 mg. 2, 3
• At hypnotic doses (3–6 mg), doxepin exhibits minimal anticholinergic activity, making it especially suitable for elderly patients. 2, 3

Suvorexant 10 mg (orexin-receptor antagonist) reduces wake after sleep onset by 16–28 minutes and carries a lower risk of cognitive and psychomotor impairment than benzodiazepine-type agents. 1, 2, 3

For Combined Sleep-Onset and Maintenance Insomnia

Eszopiclone 2–3 mg (1 mg if age ≥65 years or hepatic impairment) improves both sleep onset and maintenance, increasing total sleep time by 28–57 minutes with moderate-to-large improvements in subjective sleep quality. 1, 2, 3, 4

• Take within 30 minutes of bedtime with ≥7 hours remaining before awakening. 2, 3
• If 2 mg is tolerated but insufficient after 1–2 weeks, increase to 3 mg (maximum 2 mg for age ≥65 years). 2, 3

Temazepam 15 mg increases total sleep time by ~99 minutes but carries higher risks of dependence, falls, and cognitive impairment compared to non-benzodiazepines. 1, 4

---

Medications Explicitly NOT Recommended

Trazodone (Strong Recommendation Against)

The American Academy of Sleep Medicine explicitly recommends against trazodone for insomnia because it yields only a ~10-minute reduction in sleep latency and ~8-minute reduction in wake after sleep onset, with no improvement in subjective sleep quality and adverse events in ~75% of older adults. 1, 2, 3, 4

Over-the-Counter Antihistamines (Strong Recommendation Against)

Diphenhydramine and doxylamine are not recommended due to lack of efficacy data, strong anticholinergic effects (confusion, urinary retention, falls, daytime sedation, delirium), and tolerance development within 3–4 days. 1, 2, 3, 4

Traditional Benzodiazepines (Strong Recommendation Against)

Lorazepam, temazepam, clonazepam, and diazepam should be avoided as first-line treatment due to higher risks of dependence, withdrawal seizures, falls, cognitive impairment, respiratory depression, and associations with dementia and fractures. 1, 2, 3

Antipsychotics (Strong Recommendation Against)

Quetiapine and olanzapine must not be used for primary insomnia due to weak evidence for benefit and significant risks including weight gain, metabolic syndrome, extrapyramidal symptoms, and increased mortality in elderly patients with dementia. 1, 2, 3

Melatonin Supplements (Not Recommended)

Melatonin supplements produce only a ~9-minute reduction in sleep latency with insufficient evidence for chronic insomnia treatment. 1, 2, 4

Herbal Supplements (Not Recommended)

Valerian and L-tryptophan have insufficient evidence to support use for primary insomnia. 1, 4

---

Treatment Algorithm

Step 1: Immediate CBT-I Initiation (Week 0)

• Implement all five core CBT-I components (stimulus control, sleep restriction, cognitive restructuring, relaxation, sleep hygiene). 2, 3, 4
• Obtain 2-week sleep diary documenting bedtime, wake times, sleep latency, awakenings, total sleep time, and naps. 2, 3

Step 2: Add Pharmacotherapy if CBT-I Insufficient (Week 4–8)

Match medication to insomnia phenotype:

• Sleep-onset difficulty → zaleplon, ramelteon, or zolpidem (age-adjusted dosing). 1, 2, 3, 4
• Sleep-maintenance difficulty → low-dose doxepin or suvorexant. 1, 2, 3, 4
• Combined difficulty → eszopiclone or zolpidem extended-release. 1, 2, 3, 4

Step 3: Reassess After 1–2 Weeks

• Evaluate sleep-onset latency, total sleep time, nocturnal awakenings, and daytime functioning. 1, 2, 3
• Monitor for adverse effects: morning sedation, cognitive impairment, complex sleep behaviors (sleep-driving, sleep-walking, sleep-eating). 1, 2, 3
• If insufficient response, switch to an alternative agent within the same class rather than adding a second hypnotic. 2, 3

Step 4: Duration and Tapering (Week 4+)

• FDA labeling limits hypnotic use to ≤4 weeks for acute insomnia; evidence beyond 4 weeks is limited. 1, 2, 3
• Use the lowest effective dose for the shortest duration possible. 1, 2, 3
• Taper gradually when discontinuing to avoid rebound insomnia, while maintaining CBT-I techniques. 2, 3
• If insomnia persists beyond 7–10 days despite treatment, evaluate for underlying sleep disorders (obstructive sleep apnea, restless-legs syndrome, periodic limb movement disorder, circadian-rhythm disorders). 2, 3

---

Special Population Dosing

Elderly Patients (≥65 Years)

• Zolpidem maximum 5 mg (not 10 mg) due to increased sensitivity and fall risk. 1, 2, 3
• Eszopiclone maximum 2 mg (not 3 mg) to reduce fall and cognitive impairment risk. 1, 2, 3
• Low-dose doxepin 3 mg and ramelteon 8 mg are the safest first-line choices for elderly patients due to minimal fall risk and cognitive impairment. 2, 3

Hepatic Impairment

• Eszopiclone maximum 2 mg due to reduced clearance. 2, 3
• Zaleplon maximum 5 mg due to 70% reduction in clearance with compensated cirrhosis. 2, 3

Patients with Substance-Use History

• Ramelteon 8 mg is the only appropriate choice due to zero abuse potential and non-DEA-scheduled status. 2, 3

---

Critical Safety Warnings

Complex Sleep Behaviors (FDA Black-Box Warning)

All benzodiazepine-receptor agonists (eszopiclone, zolpidem, zaleplon) carry FDA warnings for complex sleep behaviors (sleep-driving, sleep-walking, sleep-eating); discontinue immediately if these occur. 1, 2, 3

Next-Day Impairment

• Eszopiclone 3 mg produces measurable psychomotor and memory deficits up to 11.5 hours after dosing; patients often do not perceive the impairment. 2, 3
• Avoid driving or operating machinery until fully awake. 2, 3

Falls, Fractures, and Cognitive Decline

All hypnotics increase risk of falls, fractures, and cognitive decline, especially in adults ≥65 years; observational data suggest possible associations with dementia. 1, 2, 3

Avoid Alcohol

Alcohol must be avoided while using these agents because it markedly increases the risk of complex sleep behaviors and respiratory depression. 2, 3

---

Common Pitfalls to Avoid

• Do not prescribe hypnotics without first implementing CBT-I—this violates strong guideline recommendations and yields less durable benefit. 1, 2, 3
• Do not use adult dosing in elderly patients—age-adjusted dosing (e.g., zolpidem ≤5 mg, eszopiclone ≤2 mg) is mandatory to reduce fall risk. 1, 2, 3
• Do not combine multiple sedating agents (e.g., adding a benzodiazepine to doxepin)—this markedly increases risk of respiratory depression, falls, cognitive impairment, and complex sleep behaviors. 2, 3
• Do not continue pharmacotherapy long-term without periodic reassessment (every 2–4 weeks)—efficacy, side effects, and continued need must be evaluated. 1, 2, 3
• Do not prescribe trazodone, OTC antihistamines, antipsychotics, or traditional benzodiazepines for primary insomnia—they lack efficacy and carry significant safety concerns. 1, 2, 3, 4
• Do not use zaleplon for sleep-maintenance problems—its ~1-hour half-life makes it ineffective for wake-after-sleep-onset complaints; switch to low-dose doxepin or suvorexant instead. 2, 3